Our new paper: Label-free single cell RNA-sequencing leveraging genetix variability: www.nature.com/articles/s41... 🔥🔥

Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!

@ptarantinomd.bsky.social @markuseckstein3.bsky.social

Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24

Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS)
✅ 6 & 12 mo CR: 94% & 81%
✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76%
✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs
Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social

Great review! NECTIN4 is an exciting target. More to come !
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study

www.annalsofoncology.org/article/S092...

Nice overview on "Emerging ADCs for platinum-refractory UC" from #BLADDR in Vienna! 🚨

ADCs and small molecules came to stay and will likely advance cancer treatment of multiple cancers significantly !

Incredible improvement for patient with microsatellite unstable metastatic colorectal cancer. MSI is a Ferrari ride for cancer evolution, but immunotherapy is the perfect match to stop that ride !!! Don’t think that we will see similar success for other „biomarkers“ soon.
nej.md/4eGp1tj

Incredible improvement for patient with microsatellite unstable metastatic colorectal cancer. MSI is a Ferrari ride for cancer evolution, but immunotherapy is the perfect match to stop that ride !!! Don’t think that we will see similar success for other „biomarkers“ soon.
nej.md/4eGp1tj

Nice overview on "Emerging ADCs for platinum-refractory UC" from #BLADDR in Vienna! 🚨

ADCs and small molecules came to stay and will likely advance cancer treatment of multiple cancers significantly !

The Future of Pathology: 3 Innovations Set to Revolutionize Healthcare

🔥 Pathology is entering a new era, and these groundbreaking advancements are about to transform how we diagnose and treat diseases.

Have you ever heard about SDHB deficient renal cell carcinoma 🕵️‍♂️?
SDHB-deficient kidney cancer is a rare but highly aggressive tumor, often striking patients at a younger age—typically in their 30s and 40s. 🧬 Linked to hereditary mutations in the SDHB gene, it carries a poor prognosis.

2️⃣ Digital Pathology and Remote Consultations
Gone are the days of solely relying on glass slides under microscopes. Digital pathology converts these slides into high-resolution images that can be shared instantly across the globe. This enables real-time collaboration among experts.

1️⃣ Artificial Intelligence in Diagnostics
AI is becoming an indispensable tool for pathologists. Machine learning algorithms can analyze complex medical images with incredible speed and accuracy, detecting anomalies that might be missed by the human eye.

Differential diagnosis of abdominal pain

Differential diagnosis of abdominal pain

Have you ever heard about SDHB deficient renal cell carcinoma 🕵️‍♂️?
SDHB-deficient kidney cancer is a rare but highly aggressive tumor, often striking patients at a younger age—typically in their 30s and 40s. 🧬 Linked to hereditary mutations in the SDHB gene, it carries a poor prognosis.

The Future of Pathology: 3 Innovations Set to Revolutionize Healthcare

🔥 Pathology is entering a new era, and these groundbreaking advancements are about to transform how we diagnose and treat diseases.